Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Phase 2 Completed 192 enrolled Merck & Co., Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.

Timeline

Start: 2008-09-17
Primary completion: 2009-02-24
Completion: 2009-02-24

Publications

Results Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Sep;56(9):4608-13. doi: 10.1128/AAC.00458-12. Epub 2012 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TR-701	Small molecule	200 mg	Oral
Subject	TR-701	Small molecule	300 mg	Oral
Subject	TR-701	Small molecule	400 mg	Oral

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Summary

Timeline

Publications

Drugs

Indications